The viability, self-renewal capacity, and tumorigenicity of CD133+ BTSC GBM cells involve signaling through the VEGF-VEGFR2-NRP1 axis, which may counteract the effect of anti-angiogenic therapy with bevacizumab. The gene discussed is NRP1; the disease is glioblastoma.